EUCTR2010-021528-81-HU进行中（未招募）不适用
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children aged 2 to 10 Years - Not available
ovartis Vaccines and Diagnostics s.r.l.0 个研究点目标入组 1,400 人开始时间: 2011年1月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male and female subjects: a)Healthy infants 2½ months of age (71 -79 days, inclusive), (only applicable to group I). b)Healthy infants 3½ months of age (101 -109 days, inclusive), (only applicable to group II). c)Healthy infants 6 months of age (only applicable to group III) (The age windowis defined as the first day the subject turns 6 months of age up to the day before the subject turns 7 months of age).
- •d)Healthy children 2 to 5 years of age (only applicable to group IVa) (The age window is defined as the first day the subject turns 2 years of age up to the day before the subject turns 6 years of age). e) Healthy children 6 to 10 years of age (only applicable to group IVb). (The age window is defined as the first day the subject turns 6 years of age up to the day before the subject turns 11 years of age). f) Healthy infants 3 months of age (applicable to Groups V and VI).
- •2.For whom parent(s)/legal guardian(s) have given written informed consent according to local regulations after the nature of the study has been explained;
- •3.Available for all the visits scheduled in the study;
- •4.Individuals in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1400
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subjects whose parent(s)/legal guardian(s) are unwilling or unable to give written informed consent to participate in the study;
- •2.Children's parents or legal guardian who are not able to comprehend and to follow all required study procedures for the whole period of the study.
- •3.History of any meningococcal B vaccine administration;
- •4.Previous ascertained or suspected disease caused by N. meningitidis;
- •5.Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis;
- •6.History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component
- •7.Significant acute or chronic infection within the previous 7 days or temperature higher than 38 Centigrade within the previous day of receiving the study vaccine;
- •8.Antibiotics treatment within 6 days prior to enrollment;
- •9.Individuals with history of allergy to vaccine components.
- •10.Any serious chronic or progressive disease according to the judgment of the investigator (e.g., neoplasm, diabetes mellitus Type I, cardiac disease, hepatic disease, neurological disease or seizure, either associated with fever or as part of an underlying neurological disorder or syndrome, autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
- •11.Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, use of high dose systemic corticosteroids or chronic use of inhaled high-potency corticosteroids within 14 days prior to enrollment (use of low or moderate doses of inhaled steroids is not an exclusion);
- •See protocol
研究者
相似试验
进行中（未招募）
不适用
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children aged 2 to 10 YearsEstudio fase 3B, abierto y multicéntrico para evaluar la seguridad, tolerabilidad e inmunogenicidad de la vacuna meningocócica recombinante B de Novartis cuando se administra sola a bebés sanos según diferentes programas de inmunización y a niños sanos de entre 2 y 10 años.EUCTR2010-021528-81-ESovartis Vaccines and Diagnostics s.r.l.1,150
进行中（未招募）
1 期
A clinical study to evaluate immune responses to rabies vaccine in adults who received different primary rabies vaccination regimensMedDRA version: 20.0Level: PTClassification code 10037742Term: RabiesSystem Organ Class: 10021881 - Infections and infestationsRabiesEUCTR2015-000382-31-DEGlaxoSmithKline Biologicals S.A.578
未知
3 期
A Phase III long-term study of TAK-536TCH in patients with essential hypertensioEssential hypertensionJPRN-jRCT2080222638TAKEDA PHARMACEUTICAL COMPANY LTD.341
进行中（未招募）
不适用
This clinical study investigates the effectiveness and safety of Biostate in children with Haemophilia A, a blood clotting disorder. An up to 3 day investigation of the pharmacokinetics (metabolism of Biostate by the child's body) is a part of the investigation – 0.5, 4, 8, 12, 24 and 48h after administration.EUCTR2009-015112-18-BGCSL Behring GmbH24
招募中
3 期
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the steroid administration risk groupsuperficial esophageal cancerJPRN-jRCT2063200048Kanai Nobuo17